Zhexue Qin1, Xi Liu1, Mingbao Song1, Quan Zhou2, Jie Yu1, Baoshang Zhou3, Yazhou Wu4, Yongming He1, Lan Huang5. 1. Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China. 2. Department of Science and Education, First People's Hospital of Changde City, No. 818 Renming Road, Changde, Hunan, 415003, China. 3. Department of Nephrology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China. 4. Department of Health Statistics, College of Preventive Medicine, Third Military Medical University, Chongqing, 400038, China. 5. Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China. Electronic address: huanglan260@126.com.
Abstract
BACKGROUND AND AIMS: The prognostic value of fibroblast growth factor 23 (FGF23) for mortality remains controversial. We performed a meta-analysis of cohort studies to examine the controversial relationship between FGF23 and mortality. METHODS: PubMed, EMBASE, the Cochrane Library databases and reference bibliographies were searched through September 2016 to identify prospective cohort studies with relative risks (RRs) and 95% confidence intervals (CIs) for FGF23 and mortality. A random effects model was used to pool the risk estimates. A dose-response analysis of the risk for all-cause mortality associated with FGF23 was conducted using the generalized least squares trend estimation method. RESULTS: Nineteen prospective cohort studies were eligible for inclusion in this meta-analysis, of which 16 reported all-cause mortality and 9 reported cardiovascular mortality. During the follow-up periods ranging from 1 to 18.6 years, 5606 deaths occurred among 22,805 participants and 2458 cardiovascular deaths occurred among 28,845 participants. Elevated FGF23 was associated with an increased risk of all-cause mortality (RR 1.68; 95% CI 1.48-1.92) and cardiovascular mortality (RR 1.68; 95% CI 1.38-2.04) with moderate heterogeneity. These associations were not markedly modified by the geographic location, follow-up length, patient predisposition, FGF23 measurement or study quality. A sensitivity analysis yielded a similar effect on the pooled risk estimate. Evidence of a nonlinear relationship between FGF23 and all-cause mortality was observed in the dose-response analysis, with the risk gradually increasing as FGF23 increased. CONCLUSIONS: This meta-analysis showed that individuals with increased plasma FGF23 levels might suffer a higher risk of all-cause mortality and cardiovascular mortality.
BACKGROUND AND AIMS: The prognostic value of fibroblast growth factor 23 (FGF23) for mortality remains controversial. We performed a meta-analysis of cohort studies to examine the controversial relationship between FGF23 and mortality. METHODS: PubMed, EMBASE, the Cochrane Library databases and reference bibliographies were searched through September 2016 to identify prospective cohort studies with relative risks (RRs) and 95% confidence intervals (CIs) for FGF23 and mortality. A random effects model was used to pool the risk estimates. A dose-response analysis of the risk for all-cause mortality associated with FGF23 was conducted using the generalized least squares trend estimation method. RESULTS: Nineteen prospective cohort studies were eligible for inclusion in this meta-analysis, of which 16 reported all-cause mortality and 9 reported cardiovascular mortality. During the follow-up periods ranging from 1 to 18.6 years, 5606 deaths occurred among 22,805 participants and 2458 cardiovascular deaths occurred among 28,845 participants. Elevated FGF23 was associated with an increased risk of all-cause mortality (RR 1.68; 95% CI 1.48-1.92) and cardiovascular mortality (RR 1.68; 95% CI 1.38-2.04) with moderate heterogeneity. These associations were not markedly modified by the geographic location, follow-up length, patient predisposition, FGF23 measurement or study quality. A sensitivity analysis yielded a similar effect on the pooled risk estimate. Evidence of a nonlinear relationship between FGF23 and all-cause mortality was observed in the dose-response analysis, with the risk gradually increasing as FGF23 increased. CONCLUSIONS: This meta-analysis showed that individuals with increased plasma FGF23 levels might suffer a higher risk of all-cause mortality and cardiovascular mortality.
Authors: Charles Ginsberg; Timothy E Craven; Michel B Chonchol; Alfred K Cheung; Mark J Sarnak; Walter T Ambrosius; Anthony A Killeen; Kalani L Raphael; Udayan Y Bhatt; Jing Chen; Glenn M Chertow; Barry I Freedman; Suzanne Oparil; Vasilios Papademetriou; Barry M Wall; Clinton B Wright; Joachim H Ix; Michael G Shlipak Journal: Clin J Am Soc Nephrol Date: 2018-11-13 Impact factor: 8.237
Authors: Shilpa Sharma; Ronit Katz; Charles Ginsberg; Alexander Bullen; Volker Vallon; Scott Thomson; Orson W Moe; Andrew N Hoofnagle; Peter W de Leeuw; Abraham A Kroon; Alfons J H M Houben; Joachim H Ix Journal: J Bone Miner Res Date: 2022-04-25 Impact factor: 6.390
Authors: Shilpa Sharma; Ronit Katz; Alexander L Bullen; Paulo H M Chaves; Peter W de Leeuw; Abraham A Kroon; Alfons J H M Houben; Michael G Shlipak; Joachim H Ix Journal: J Clin Endocrinol Metab Date: 2020-12-01 Impact factor: 5.958
Authors: Valerie K Sullivan; Lawrence J Appel; Jesse C Seegmiller; Scott T McClure; Casey M Rebholz Journal: J Nutr Date: 2021-10-01 Impact factor: 4.687
Authors: Gary C Chan; Jasmin Divers; Gregory B Russell; Carl D Langefeld; Lynne E Wagenknecht; Fang-Chi Hsu; Jianzhao Xu; S Carrie Smith; Nicholette D Palmer; Pamela J Hicks; Donald W Bowden; Thomas C Register; Lijun Ma; J Jeffrey Carr; Barry I Freedman Journal: Diabetes Care Date: 2017-11-07 Impact factor: 19.112
Authors: Natalia Campos-Obando; Lies Lahousse; Guy Brusselle; Bruno H Stricker; Albert Hofman; Oscar H Franco; André G Uitterlinden; M Carola Zillikens Journal: Eur J Epidemiol Date: 2018-05-15 Impact factor: 8.082
Authors: Simon Correa; David A Morrow; Eugene Braunwald; Richard Y Davies; Erica L Goodrich; Sabina A Murphy; Christopher P Cannon; Michelle L O'Donoghue Journal: J Am Heart Assoc Date: 2018-10-16 Impact factor: 5.501
Authors: Shilpa Sharma; Ronit Katz; Ruth F Dubin; David A Drew; Orlando M Gutierrez; Michael G Shlipak; Mark J Sarnak; Joachim H Ix Journal: J Am Geriatr Soc Date: 2020-11-10 Impact factor: 7.538